These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28246275)

  • 1. Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
    Xu Q; Li Y; Lv N; Jing Y; Xu Y; Li Y; Li W; Yao Z; Chen X; Huang S; Wang L; Li Y; Yu L
    Clin Cancer Res; 2017 Aug; 23(15):4511-4522. PubMed ID: 28246275
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic value of IDH2R140 and IDH2R172 mutations in patients with acute myeloid leukemia: a systematic review and meta-analysis.
    Qin Y; Shen K; Liu T; Ma H
    BMC Cancer; 2023 Jun; 23(1):527. PubMed ID: 37291515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.
    Damm F; Thol F; Hollink I; Zimmermann M; Reinhardt K; van den Heuvel-Eibrink MM; Zwaan CM; de Haas V; Creutzig U; Klusmann JH; Krauter J; Heuser M; Ganser A; Reinhardt D; Thiede C
    Leukemia; 2011 Nov; 25(11):1704-10. PubMed ID: 21647152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
    Wang R; Gao X; Yu L
    BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
    Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
    Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
    DiNardo CD; Ravandi F; Agresta S; Konopleva M; Takahashi K; Kadia T; Routbort M; Patel KP; Mark Brandt ; Pierce S; Garcia-Manero G; Cortes J; Kantarjian H
    Am J Hematol; 2015 Aug; 90(8):732-6. PubMed ID: 26016821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
    Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Issa G; Furudate K; Tanaka T; Pierce S; Tang G; Patel KP; Medeiros J; Abbas HA; Haddad F; Hammond D; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Pemmaraju N; Konopleva M; Garcia-Manero G; Ravandi F; Kadia TM; Loghavi S; DiNardo CD
    Am J Hematol; 2022 Nov; 97(11):1443-1452. PubMed ID: 36054614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia].
    Wu RY; Xie XS; Wei Y; Jang ZX; Chen DD; Sun H; Wan DM; Liu YF; Sun L
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):39-44. PubMed ID: 33677867
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.
    Zhou KG; Jiang LJ; Shang Z; Wang J; Huang L; Zhou JF
    Leuk Lymphoma; 2012 Dec; 53(12):2423-9. PubMed ID: 22616558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].
    Wang RX; Wu DP; Chen SN; He J; Xu Y; Wang XL; Yin J; Tian H; Tian XP; Sun AN
    Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(10):751-5. PubMed ID: 23755812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience.
    Ambinder A; Smith M; Tsai HL; Varadhan R; DeZern A; Dalton W; Gocke C; Webster J; Gondek L; Gojo I; Ali SA; Huff CA; Swinnen L; Wagner-Johnston N; Showel M; Prince G; Borrello I; Bolaños-Meade J; Luznik L; Jain T; Imus P; Fuchs E; Ambinder R; Gladstone DE; Levis M; Jones R; Ghiaur G; Smith BD
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):260-269. PubMed ID: 34750086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
    Brunner AM; Neuberg DS; Wander SA; Sadrzadeh H; Ballen KK; Amrein PC; Attar E; Hobbs GS; Chen YB; Perry A; Connolly C; Joseph C; Burke M; Ramos A; Galinsky I; Yen K; Yang H; Straley K; Agresta S; Adamia S; Borger DR; Iafrate A; Graubert TA; Stone RM; Fathi AT
    Cancer; 2019 Feb; 125(4):541-549. PubMed ID: 30422308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.
    Bill M; Jentzsch M; Bischof L; Kohlschmidt J; Grimm J; Schmalbrock LK; Backhaus D; Brauer D; Goldmann K; Franke GN; Vucinic V; Niederwieser D; Mims AS; Platzbecker U; Eisfeld AK; Schwind S
    Blood Adv; 2023 Feb; 7(3):436-444. PubMed ID: 35381077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate dehydrogenase mutations in myeloid malignancies.
    Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
    Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
    Thol F; Damm F; Wagner K; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Heil G; Heuser M; Krauter J; Ganser A
    Blood; 2010 Jul; 116(4):614-6. PubMed ID: 20421455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
    Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia.
    Chou WC; Lei WC; Ko BS; Hou HA; Chen CY; Tang JL; Yao M; Tsay W; Wu SJ; Huang SY; Hsu SC; Chen YC; Chang YC; Kuo KT; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
    Leukemia; 2011 Feb; 25(2):246-53. PubMed ID: 21079611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy for isocitrate dehydrogenase 2 (IDH2)
    Linch DC; Hills RK; Burnett AK; Russell N; Gale RE
    Br J Haematol; 2022 Mar; 196(6):1348-1352. PubMed ID: 34870324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
    Abbas S; Lugthart S; Kavelaars FG; Schelen A; Koenders JE; Zeilemaker A; van Putten WJ; Rijneveld AW; Löwenberg B; Valk PJ
    Blood; 2010 Sep; 116(12):2122-6. PubMed ID: 20538800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.